Lenalidomide Restrains Motility and Overangiogenic Potential of Bone Marrow Endothelial Cells in Patients with Active Multiple Myeloma

Purpose: To determine the in vivo and in vitro antiangiogenic power of lenalidomide, a “lead compound” of IMiD immunomodulatory drugs in bone marrow (BM) endothelial cells (EC) of patients with multiple myeloma (MM) in active phase (MMEC). Experimental Design: The antiangiogenic effect in vivo was studied using the chorioallantoic membrane (CAM) assay. Functional studies in vitro (angiogenesis, “wound” healing and chemotaxis, cell viability, adhesion, and apoptosis) were conducted in both primary MMECs and ECs of patients with monoclonal gammopathies (MGUS) of undetermined significance (MGEC) or healthy human umbilical vein endothelial cells (HUVEC). Real-time reverse transcriptase PCR, Western blotting, and differential proteomic analysis were used to correlate morphologic and biological EC features with the lenalidomide effects at the gene and protein levels. Results: Lenalidomide exerted a relevant antiangiogenic effect in vivo at 1.75 μmol/L, a dose reached in interstitial fluids of patients treated with 25 mg/d. In vitro, lenalidomide inhibited angiogenesis and migration of MMECs, but not of MGECs or control HUVECs, and had no effect on MMEC viability, apoptosis, or fibronectin- and vitronectin-mediated adhesion. Lenalidomide-treated MMECs showed changes in VEGF/VEGFR2 signaling pathway and several proteins controlling EC motility, cytoskeleton remodeling, and energy metabolism pathways. Conclusions: This study provides information on the molecular mechanisms associated with the antimigratory and antiangiogenic effects of lenalidomide in primary MMECs, thus giving new avenues for effective endothelium-targeted therapies in MM. Clin Cancer Res; 17(7); 1935–46. ©2011 AACR.

[1]  R. Shaker,et al.  Thalidomide inhibits inflammatory and angiogenic activation of human intestinal microvascular endothelial cells (HIMEC). , 2010, American journal of physiology. Gastrointestinal and liver physiology.

[2]  M. Dutsch-Wicherek.  REVIEW ARTICLE: RCAS1, MT, and Vimentin as Potential Markers of Tumor Microenvironment Remodeling , 2010, American journal of reproductive immunology.

[3]  J. Hampe,et al.  Increased proteasome subunit protein expression and proteasome activity in colon cancer relate to an enhanced activation of nuclear factor E2-related factor 2 (Nrf2) , 2009, Oncogene.

[4]  M. Maffia,et al.  Serum proteomic profile of cutaneous malignant melanoma and relation to cancer progression: association to tumor derived alpha-N-acetylgalactosaminidase activity. , 2009, Cancer letters.

[5]  A. Wittinghofer,et al.  GTP-induced conformational changes in septins and implications for function , 2009, Proceedings of the National Academy of Sciences.

[6]  D. Ribatti,et al.  Gene Expression Profiling of Bone Marrow Endothelial Cells in Patients with Multiple Myeloma , 2009, Clinical Cancer Research.

[7]  Neil Vargesson,et al.  Thalidomide induces limb defects by preventing angiogenic outgrowth during early limb formation , 2009, Proceedings of the National Academy of Sciences.

[8]  Lei Wu,et al.  The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions. , 2009, Microvascular research.

[9]  S. Gibson,et al.  The role of Bcl-2 family member BNIP3 in cell death and disease: NIPping at the heels of cell death , 2009, Cell Death and Differentiation.

[10]  D. Ribatti,et al.  Validation of PDGFRbeta and c-Src tyrosine kinases as tumor/vessel targets in patients with multiple myeloma: preclinical efficacy of the novel, orally available inhibitor dasatinib. , 2008, Blood.

[11]  Alessandro Corso,et al.  Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. , 2007, The New England journal of medicine.

[12]  Lei Wu,et al.  The anticancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions , 2007 .

[13]  P. L. Bergsagel,et al.  Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma. , 2007, Mayo Clinic proceedings.

[14]  Charles P. Lin,et al.  Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma. , 2007, Blood.

[15]  C. Wernstedt,et al.  Src kinase phosphorylates vascular endothelial-cadherin in response to vascular endothelial growth factor: identification of tyrosine 685 as the unique target site , 2007, Oncogene.

[16]  Raed A Dweik,et al.  Alterations of cellular bioenergetics in pulmonary artery endothelial cells , 2007, Proceedings of the National Academy of Sciences.

[17]  P. Gunning,et al.  Alterations in γ-Actin and Tubulin-Targeted Drug Resistance in Childhood Leukemia , 2006 .

[18]  Nathan I. Lopez,et al.  Selenoprotein W during development and oxidative stress. , 2006, Journal of inorganic biochemistry.

[19]  S. Bicciato,et al.  Thalidomide downregulates angiogenic genes in bone marrow endothelial cells of patients with active multiple myeloma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  D. Ribatti,et al.  Bone marrow endothelial cells in multiple myeloma secrete CXC‐chemokines that mediate interactions with plasma cells , 2005, British journal of haematology.

[21]  J. C. Wilkinson,et al.  The Small Heat Shock Protein αB-crystallin Is a Novel Inhibitor of TRAIL-induced Apoptosis That Suppresses the Activation of Caspase-3* , 2005, Journal of Biological Chemistry.

[22]  G. Christé,et al.  Vascular Endothelial–Cadherin Tyrosine Phosphorylation in Angiogenic and Quiescent Adult Tissues , 2005, Circulation research.

[23]  J. Pouysségur,et al.  Regulation of Tumor Cell Motility by ERK Mitogen‐Activated Protein Kinases , 2004, Annals of the New York Academy of Sciences.

[24]  D. Guidolin,et al.  A VEGF-dependent autocrine loop mediates proliferation and capillarogenesis in bone marrow endothelial cells of patients with multiple myeloma , 2004, Thrombosis and Haemostasis.

[25]  H. Stein,et al.  Jagged1-induced Notch signaling drives proliferation of multiple myeloma cells. , 2004, Blood.

[26]  Angus G. Dalgleish,et al.  The evolution of thalidomide and its IMiD derivatives as anticancer agents , 2004, Nature Reviews Cancer.

[27]  D. Guidolin,et al.  A new image analysis method based on topological and fractal parameters to evaluate the angiostatic activity of docetaxel by using the Matrigel assay in vitro. , 2004, Microvascular research.

[28]  G. Xiao,et al.  Deregulation of NF-κB and its upstream kinases in cancer , 2003, Cancer and Metastasis Reviews.

[29]  D. Guidolin,et al.  Endothelial cells in the bone marrow of patients with multiple myeloma. , 2003, Blood.

[30]  Kenneth C. Anderson,et al.  Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group , 2003, British journal of haematology.

[31]  A. Dalgleish,et al.  Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects , 2002, British Journal of Cancer.

[32]  Richard LeBlanc,et al.  Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. , 2002, Blood.

[33]  A. Dalgleish,et al.  Thalidomide and its analogues have distinct and opposing effects on TNF‐α and TNFR2 during co‐stimulation of both CD4+ and CD8+ T cells , 2002, Clinical and experimental immunology.

[34]  N. Munshi,et al.  Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications. , 2002, Blood.

[35]  Michael Karin,et al.  NF-κB in cancer: from innocent bystander to major culprit , 2002, Nature Reviews Cancer.

[36]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[37]  D Shugar,et al.  Purine nucleoside phosphorylases: properties, functions, and clinical aspects. , 2000, Pharmacology & therapeutics.

[38]  C. Bucana,et al.  Blockade of nuclear factor-kappaB signaling inhibits angiogenesis and tumorigenicity of human ovarian cancer cells by suppressing expression of vascular endothelial growth factor and interleukin 8. , 2000, Cancer research.

[39]  T. Abe,et al.  Expression of the 37-kDa laminin binding protein in murine lung tumor cell correlates with tumor angiogenesis. , 2000, Cancer letters.

[40]  A. Reynolds,et al.  The p120 catenin family: complex roles in adhesion, signaling and cancer. , 2000, Journal of cell science.

[41]  P. Schwartzberg,et al.  Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability. , 1999, Molecular cell.

[42]  P. Haslett,et al.  Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. , 1999, Journal of immunology.

[43]  D. Ribatti,et al.  Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. , 1999, Blood.

[44]  S. Mahooti,et al.  Distinct signal transduction pathways are utilized during the tube formation and survival phases of in vitro angiogenesis. , 1998, Journal of cell science.

[45]  M. Corada,et al.  Vascular endothelial growth factor induces VE-cadherin tyrosine phosphorylation in endothelial cells. , 1998, Journal of cell science.

[46]  D. Linzer,et al.  Printed in U.S.A. Copyright © 1997 by The Endocrine Society Proliferin Induces Endothelial Cell Chemotaxis through a G Protein-Coupled, Mitogen-Activated Protein Kinase- Dependent Pathway* , 1997 .

[47]  M. Shibuya,et al.  Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. , 1994, The Journal of biological chemistry.

[48]  Marco Presta,et al.  The gelatin sponge–chorioallantoic membrane assay , 2006, Nature Protocols.

[49]  P. Gunning,et al.  Alterations in gamma-actin and tubulin-targeted drug resistance in childhood leukemia. , 2006, Journal of the National Cancer Institute.

[50]  A. Dalgleish,et al.  Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. , 2005, Microvascular research.

[51]  M. Wu.  Roles of the stress-induced gene IEX-1 in regulation of cell death and oncogenesis , 2004, Apoptosis.

[52]  G. Xiao,et al.  Deregulation of NF-kappaB and its upstream kinases in cancer. , 2003, Cancer metastasis reviews.

[53]  J. Reichelt,et al.  Keratins: a structural scaffold with emerging functions , 2003, Cellular and Molecular Life Sciences CMLS.

[54]  Wu Mx.  Roles of the stress-induced gene IEX-1 in regulation of cell death and oncogenesis. , 2003 .

[55]  Michael Karin,et al.  NF-kappaB in cancer: from innocent bystander to major culprit. , 2002, Nature reviews. Cancer.